[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-376580-105":59,"doc-detail-376580-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomics-driven-precision-medicine-in-pediatric-solid-tumors-review","Genomics-Driven Precision Medicine in Pediatric Solid Tumors - Review","","Genomic testing in cancer has enabled biomarker-driven precision therapy, yielding improved outcomes and progression-free survival in many adult malignancies. In pediatric cancers, translation has been slower due to distinctive mutation profiles, limited sample availability, and a low frequency of recurrent genomic alterations. New efforts in childhood oncology have identified genomic aberrations and transcriptomic patterns, creating opportunities to study rare, hard-to-access neoplasms. This review summarizes current and potential genetic markers and outlines future directions for more precise therapeutic strategies in pediatric solid tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomics-driven-precision-medicine-in-pediatric-solid-tumors-review/376580/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomics-driven-precision-medicine-in-pediatric-solid-tumors-review/376580.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the review on pediatric precision oncology?","Question",{"text":112,"@type":113},"The review outlines the current landscape of genomic targets for pediatric precision medicine and highlights examples of trial designs, contrasting pediatric progress with adult cancer research.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why has precision medicine advanced more slowly in pediatric cancers than in adults?",{"text":117,"@type":113},"Progress has been slower because pediatric tumors have distinct mutation profiles, fewer accessible samples, and fewer well-defined recurrent genomic alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"What types of molecular information are emphasized for pediatric solid tumors?",{"text":121,"@type":113},"The document emphasizes genomic aberrations and transcriptomic profiles as promising opportunities to study rare and difficult-to-access neoplasms and to develop targeted treatment strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},376580,1790804626,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","cancers   \nReview  \nGenomics-Driven Precision Medicine in Pediatric Solid Tumors  \nPraewa Suthapot 1,2,3, Wararat Chiangjong 4, Parunya Chaiyawat 3,5, Pongsakorn Choochuen 2,6, Dumnoensun Pruksakorn 3,5, Surasak Sangkhathat 2,6,7, Suradej Hongeng 1, Usanarat Anurathapan 1, * and Somchai Chutipongtanate 8, *  \nCitation: Suthapot, P.; Chiangjong, W.; Chaiyawat, P.; Choochuen, P.; Pruksakorn, D.; Sangkhathat, S.; Hongeng, S.; Anurathapan, U.; Chutipongtanate, S.  \nGenomics-Driven Precision Medicine in Pediatric Solid Tumors. Cancers 2023, 15, 1418. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cancers15051418](10.3390/cancers15051418)  \nAcademic Editors: George  \nI. Lambrou and Maria Braoudaki  \nReceived: 18 January 2023  \nRevised: 10 February 2023  \nAccepted: 15 February 2023  \nPublished: 23 February 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand  \n2 Department of Biomedical Science and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand  \n3 Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand  \n4 Pediatric Translational Research Unit, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand  \n5 Musculoskeletal Science and Translational Research Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand  \n6 Translational Medicine Research Center, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand  \n7 Department of Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand  \n8 Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA  \n* [Correspondence: usanarat.anu@mahidol.ac.th](Correspondence: usanarat.anu@mahidol.ac.th) (U.A.); chutipsi@ucmail.uc.edu or [schuti.rama@gmail.com](schuti.rama@gmail.com) (S.C.)  \nSimple Summary: The detection of genomic aberrations in cancers has yielded a wealth of information to discover oncogenic drivers or pathogenic variants that are relevant for the development of precise treatment strategies. Recent studies have shown promising outcomes in adult cancer patients with well characterized cancer genetic biomarkers. However, the development of precise treatments for pediatric cancers is difficult due to the limited number of accessible samples and the fact that well-defined target genetic aberrations are limited. Here, we review the current landscape of pediatric precision oncology compared to adults and highlight the examples of single-arm and multiple-arm designs of pediatric precision treatments.  \nAbstract: Over the past decades, several study programs have conducted genetic testing in cancer patients to identify potential genetic targets for the development of precision therapeutic strategies. These biomarker-driven trials have demonstrated improved clinical outcomes and progression-free survival rates in various types of cancers, especially for adult malignancies. However, similar progress in pediatric cancers has been slow due to their distinguished mutation profiles compared to adults and the low frequency of recurrent genomic alterations. Recently, increased efforts to develop precision medicine for childhood malignancies have led to the identification of genomic alterationsand transcriptomic profiles of pediatric patients which ","cbCairFeyxtzV24E","https://ap.wps.com/l/cbCairFeyxtzV24E","pdf",853531,27,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction\n## Pediatric cancer burden and disparities\n## Genomics and rationale for precision targeting\n# Genetic markers and precision therapeutic strategies","[{\"question\":\"What is the main purpose of the review on pediatric precision oncology?\",\"answer\":\"The review outlines the current landscape of genomic targets for pediatric precision medicine and highlights examples of trial designs, contrasting pediatric progress with adult cancer research.\"},{\"question\":\"Why has precision medicine advanced more slowly in pediatric cancers than in adults?\",\"answer\":\"Progress has been slower because pediatric tumors have distinct mutation profiles, fewer accessible samples, and fewer well-defined recurrent genomic alterations.\"},{\"question\":\"What types of molecular information are emphasized for pediatric solid tumors?\",\"answer\":\"The document emphasizes genomic aberrations and transcriptomic profiles as promising opportunities to study rare and difficult-to-access neoplasms and to develop targeted treatment strategies.\"}]","Genomics-Driven Precision Medicine in Pediatric Solid Tumors - Review | PDF",1790220076,68]